Biomarkers in the Evaluation of Chronic Lung Disease
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, High Blood Pressure (Hypertension), Pulmonary |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Oncology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
| End Date: | June 2011 |
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage
migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic
inflammatory process, and that MIF may be a useful biomarker of the severity and progression
of both ILD and PH.
We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage
migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic
inflammatory process, and that MIF may be a useful biomarker of the severity and progression
of both ILD and PH.
To study this hypothesis, we have two specific aims:
1. To evaluate plasma MIF concentration as a marker of severity in ILD and PH and
2. To determine the utility of breathe condensate analysis in the evaluation of ILD and
PH. If we are successful in identifying MIF as a biomarker, it may identify MIF as a
useful therapeutic target, as we have shown in other inflammatory disorders.
We found this trial at
1
site
Click here to add this to my saved trials
